ALLMedicine™ Type 2 Diabetes Center

Jan 21st, 2021 - Weight loss has been shown to improve metabolic parameters and cardiovascular risk in people with type 2 diabetes mellitus (T2DM). This phase 2 study evaluated the safety and efficacy of JNJ-64565111, a dual agonist of GLP-1 and glucagon receptors...

Jan 21st, 2021 - Individuals with obesity have a heightened risk of developing serious comorbidities, and pharmacological treatments for people with obesity are limited. This phase 2 study assessed the safety and efficacy of JNJ-64565111, a dual agonist of glucago...

Jan 21st, 2021 - The prevalence and pathophysiological background of type 2 diabetes (T2DM) vary across ethnicities and can affect treatment responses. Adding lixisenatide to basal insulin (BI) in T2DM participants has demonstrated improvements in HbA1c and post p...

Jan 21st, 2021 - Macrovascular complications such as atherosclerosis, myocardial infarction and stroke, and microvascular complications such as nephropathy, retinopathy, and neuropathy are the major causes of increased morbidity and mortality in both type 1 and ty...

Jan 21st, 2021 - Evidence suggests that vitamin C supplementation could be a potential therapy in type 2 diabetes. However, its effectiveness and evidence quality require further evaluation. To investigate the efficacy of oral vitamin C supplementation in improvin...

Nov 16th, 2020 - Observational studies have investigated the association of risk factors with breast cancer prognosis. However, the results have been conflicting and it has been challenging to establish causality due to potential residual confounding. Using a Mend...

Nov 8th, 2020 - Among patients with type 2 diabetes (T2D), sodium-glucose cotransporter-2 (SGLT2) inhibitors dapagliflozin and empagliflozin vs canagliflozin show greater benefit in reducing gout, according to research results presented at the American College of...

Oct 8th, 2020 - Non-alcoholic fatty liver disease (NAFLD) currently represents an epidemic worldwide. NAFLD is the most frequently diagnosed chronic liver disease, affecting 20-30% of the general population. Furthermore, its prevalence is predicted to increase ex...

Sep 16th, 2020 - A recent network meta-analysis of 450 randomized clinical trials demonstrated various benefits of some newer pharmacologic diabetes agents (NEJM JW Gen Med Aug 1 2020 and Ann Intern Med 2020; 173:278). Based on these and other data, the ADA recent...

Aug 31st, 2020 - The American Diabetes Association (ADA) updates the Standards of Medical Care in Diabetes annually to provide clinicians, patients, researchers, payers, and other interested parties with evidence-based recommendations for the diagnosis and managem...

Jan 31st, 2021 - Metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Metformin hydrochloride extended-release tablets are a biguanide indicated as an...

Jan 21st, 2021 - Weight loss has been shown to improve metabolic parameters and cardiovascular risk in people with type 2 diabetes mellitus (T2DM). This phase 2 study evaluated the safety and efficacy of JNJ-64565111, a dual agonist of GLP-1 and glucagon receptors...

Jan 21st, 2021 - Individuals with obesity have a heightened risk of developing serious comorbidities, and pharmacological treatments for people with obesity are limited. This phase 2 study assessed the safety and efficacy of JNJ-64565111, a dual agonist of glucago...

Jan 21st, 2021 - The prevalence and pathophysiological background of type 2 diabetes (T2DM) vary across ethnicities and can affect treatment responses. Adding lixisenatide to basal insulin (BI) in T2DM participants has demonstrated improvements in HbA1c and post p...

Jan 21st, 2021 - Macrovascular complications such as atherosclerosis, myocardial infarction and stroke, and microvascular complications such as nephropathy, retinopathy, and neuropathy are the major causes of increased morbidity and mortality in both type 1 and ty...

Jan 19th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. People with type 2 diabetes who develop COVID-19 show a substantially reduced risk of dying if they are taking metformin, shows a new study that a...

Jan 18th, 2021 - Patients with type 2 diabetes who follow a low carbohydrate diet (LCD) for at least 6 months appear to have significantly higher remission rates than those following other diets, although the benefits diminish by 12 months, suggests a new analysis...

Jan 17th, 2021 - Use of sodium-glucose cotransporter 2 (SGLT2) inhibitors during acute COVID-19 illness raises the risk for euglycemic diabetic ketoacidosis (euDKA), a new case series suggests. Five patients with type 2 diabetes who were taking SGLT2 inhibitors pr...

Jan 17th, 2021 - Takeaway Ultra-processed food (UPF) consumption was associated with a clinically important increased risk of type 2 diabetes (T2D). The risk of incident T2D increased by 12% for every 10 percentage points increase in UPF consumption. Why this matt...

Jan 14th, 2021 - The Food and Drug Administration has determined that data collected on the dual SGLT1/2 inhibitor sotagliflozin (Zynquista) for treating patients with type 2 diabetes in the SOLOIST and SCORED pivotal trials can help support a New Drug Application...